'Briviact Patent Expiry' SK Biopharmaceuticals Targets Top Spot in Epilepsy Treatment Market with Expanded Formulations
NDA Submitted for Oral Suspension, Expanding Prescription Base
Xcopri's Annual U.S. Sales Grow 43.7% Year-Over-Year
Azetucalner Prepares for FDA Application, Intensifying Competition Variable
With the expiration of the substance patent for Briviact, developed by Belgian global pharmaceutical company UCB, in February, the epilepsy treatment market has been shaken, and attention is now focused on SK Biopharmaceuticals’ next moves. SK Biopharmaceuticals is targeting market gaps with its cenobamate (branded as Xcopri in the United States) oral suspension formulation. The company is aiming to quickly fill the void in the market by expanding prescriptions to patient groups that were difficult to reach with the existing tablet formulation.
According to the pharmaceutical and biotech industry as of April 8, SK Biopharmaceuticals recently submitted a New Drug Application (NDA) for the oral suspension formulation of cenobamate to the U.S. Food and Drug Administration (FDA). Following the existing tablet formulation, the company is seeking additional approval for this new formulation, targeting adults with partial-onset seizures (POS). The oral suspension improves dosing convenience for patients who have difficulty swallowing tablets and allows for flexible dosage adjustments, enabling the company to capture patient groups previously not accessible with tablets. According to a pharmacokinetic (PK) study presented at the American Epilepsy Society (AES) annual meeting last year, the oral suspension and the existing tablet formulation showed similar absorption and drug exposure profiles in the body, demonstrating pharmacokinetic equivalence.
This strategy is also aligned with pediatric clinical trials. SK Biopharmaceuticals is currently conducting clinical trials for pediatric patients, and based on the results of this NDA and the pediatric studies, the company plans to sequentially expand the age range for administration to include children and adolescents. A representative from SK Biopharmaceuticals stated, "From a patient-centered perspective, we plan to expand treatment options and address unmet medical needs among diverse patient groups to broaden the base of prescriptions."
The background for SK Biopharmaceuticals' aggressive approach lies in changes to the market structure. Briviact had been the number one drug by market share in the U.S. epilepsy treatment market and, alongside Xcopri, had split the third- and fourth-line prescription slots as new drugs. However, with the expiration of the patent and the launch of Briviact generics, Briviact with the same active ingredient has been pushed to the first- and second-line prescription stages, and Xcopri now exclusively occupies the third- and fourth-line new drug prescription positions. In the U.S., insurance company management systems typically require generic products to be prescribed first for epilepsy treatments, with new drugs used only if generics prove ineffective. Xcopri’s substance patent in the United States is valid until 2032, leading industry analysts to believe that the company can secure long-term market leadership over its competitors.
Cenobamate is already on a high-growth trajectory. In the United States, which accounts for about 70% of the global epilepsy treatment market, Xcopri’s quarterly sales surged from 68.4 million dollars (90.9 billion won) in the first quarter of 2024 to 124 million dollars (172.2 billion won) in the third quarter of 2025. In 2023, annual U.S. sales reached 443.2 million dollars (630.3 billion won), representing 43.7% growth over the previous year’s 321.6 million dollars (438.7 billion won). While fourth-quarter sales remained steady at 117.9 million dollars (170.8 billion won) due to seasonal factors and inventory effects during transport, the number of prescriptions reached an all-time high of 47,103 in December 2023, indicating robust underlying demand. The foundation for this growth is the clear efficacy advantage over competing drugs. SK Biopharmaceuticals commented, "To date, Xcopri is the only drug with a complete seizure freedom rate exceeding 20%." Complete seizure freedom refers to a state in which no seizures occur throughout the medication period and is a key evaluation metric for epilepsy treatments.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Heeryeong Jeong, a research analyst at Kyobo Securities, stated, "With the patent for Briviact, the leading drug, expiring in February, and with the expansion of indications (PGTC) and to pediatric age groups, significant increases in market share can be expected in 2026." However, she pointed out that Xenon Pharmaceuticals’ XEN1101 is preparing to submit a New Drug Application to the FDA in the second half of this year after releasing major Phase 3 clinical results, indicating that future competition could become a variable. Geunhee Seo, a research analyst at Samsung Securities, forecast, "Until Xenon Pharmaceuticals’ XEN1101, a potential competitor, is actually launched in the market, Xcopri’s oligopoly and high growth rate, backed by real-world evidence (RWE) and a robust marketing infrastructure, will remain intact."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.